Literature DB >> 24214917

Porcine small intestine submucosal grafts for post-tumor resection orbital reconstruction.

James Phillips1, Kristen O Riley, Bradford A Woodworth.   

Abstract

OBJECTIVES/HYPOTHESIS: Removal of the medial orbital wall for sinonasal tumor involvement is required to obtain complete oncologic resection. However, orbital fat herniation can produce significant morbidity, including enophthalmos and diplopia. The purpose of the current study was to evaluate outcomes following use of porcine small intestine submucosa (SIS) grafts for orbital reconstruction following extirpation of sinonasal malignancies. STUDY
DESIGN: Case series in a tertiary hospital setting.
METHODS: Review of prospectively collected data regarding orbital reconstruction using SIS was performed. Demographics, tumor histology, size of orbital defect, adjuvant treatment, clinical status, and complications were recorded.
RESULTS: Seventeen patients (average age, 58 years; range, 27-82 years) had SIS grafting of the medial orbital wall over a 5-year period at our tertiary academic institution. The average orbital wall defect size was 4.6 cm(2) (range, 1 cm(2)-24 cm(2)). Tumor histopathology included esthesioneuroblastoma (n = 5), squamous cell carcinoma (n = 4), adenocarcinoma (n = 2), sinonasal undifferentiated carcinoma (n = 2), melanoma (n = 3), and neuroendocrine carcinoma (n = 1). Surgical goals were curative intent in all patients. Ten patients had postoperative radiation therapy, whereas five individuals had surgical extirpation following neoadjuvant chemotherapy and radiation. All patients had complete locoregional control at last clinical follow-up (average, 16 months; range, 2-54 months), although three patients developed distant metastases. The only orbital complications noted were enophthalmos (n = 1), periorbital cellulitis (n = 1), and orbital wall crusting (n = 1).
CONCLUSIONS: SIS reconstruction of orbital wall defects was effective in the current series of patients, with only one patient developing noticeable enophthalmos and a low incidence of surgical complications. LEVEL OF EVIDENCE: 4.
© 2013 The American Laryngological, Rhinological and Otological Society, Inc.

Entities:  

Keywords:  Biodesign; Porcine small intestine submucosa; endoscopic cerebrospinal fluid leak repair; endoscopic skull base surgery; orbital reconstruction; skull base tumor

Mesh:

Year:  2013        PMID: 24214917     DOI: 10.1002/lary.24515

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  5 in total

1.  Comparison of Small Intestinal Submucosal Graft and Autologous Tissue in Prevention of CSF leak after Posterior Fossa Craniotomy.

Authors:  Douglas J Totten; Nauman F Manzoor; Kristen L Yancey; Robert J Yawn; David S Haynes; Alejandro Rivas
Journal:  J Neurol Surg B Skull Base       Date:  2021-03-12

Review 2.  Regenerative Medicine: Charting a New Course in Wound Healing.

Authors:  Geoffrey C Gurtner; Mary Ann Chapman
Journal:  Adv Wound Care (New Rochelle)       Date:  2016-07-01       Impact factor: 4.730

3.  Inaccurate Assessments of Anterior Cranial Base Malignancy Following Nasoseptal Flap Reconstruction.

Authors:  Erika Walsh; Elisa Illing; Kristen O Riley; Joel Cure; Aviva Srubiski; Richard J Harvey; Bradford A Woodworth
Journal:  J Neurol Surg B Skull Base       Date:  2015-05-15

4.  Extracellular Matrix Degradation Products Downregulate Neoplastic Esophageal Cell Phenotype.

Authors:  Lindsey T Saldin; Shil Patel; Li Zhang; Luai Huleihel; George S Hussey; David G Nascari; Lina M Quijano; Xue Li; Divya Raghu; Anant K Bajwa; Nicholas G Smith; Christopher C Chung; Ashten N Omstead; Juliann E Kosovec; Blair A Jobe; Neill J Turner; Ali H Zaidi; Stephen F Badylak
Journal:  Tissue Eng Part A       Date:  2019-03       Impact factor: 3.845

5.  Porcine small intestine graft for reconstruction of oral defects.

Authors:  Petra V Membreno; Anas A Eid; Christopher C Vanison; M Boyd Gillespie; John P Gleysteen
Journal:  Laryngoscope Investig Otolaryngol       Date:  2021-07-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.